Richard T. Kenney - Jun 30, 2025 Form 4 Insider Report for Sonnet BioTherapeutics Holdings, Inc. (SONN)

Signature
/s/ Richard T. Kenney
Stock symbol
SONN
Transactions as of
Jun 30, 2025
Transactions value $
$0
Form type
4
Date filed
8/21/2025, 04:48 PM
Previous filing
Dec 5, 2024
Next filing
Jul 15, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kenney Richard T Chief Medical Officer 100 OVERLOOK CENTER, SUITE 102, PRINCETON, /s/ Richard T. Kenney 2025-08-21 0001606653

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SONN Warrant Award +86.5K 86.5K Jun 30, 2025 Common Stock 86.5K $1.16 Direct F1
transaction SONN Warrant Award +320K 320K Jul 14, 2025 Common Stock 320K $1.25 Direct F2
transaction SONN Series 5 Preferred Stock Award +200 200 Jul 14, 2025 Common Stock 160K $1.25 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 30, 2025, the Reporting Person was issued warrants to purchase up to 86,505 shares of common stock, par value $0.0001 ("Common Stock") as partial consideration for a convertible note (the "Convertible Note") issued by the Company in favor of the Reporting Person in the principal amount of $200,000. The Convertible Note and warrants cannot be converted or exercised, respectively, to the extent that, after giving effect to such conversion or exercise, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Common Stock.
F2 On July 14, 2025, the Reporting Person was issued warrants to purchase up to 320,000 shares of Common Stock upon the conversion in full of the Convertible Note. The warrants cannot be exercised to the extent that, after giving effect to such exercise, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Common Stock.
F3 On July 14, the Reporting Person was issued 200 shares of Series 5 Preferred Stock, initially convertible at a conversion price of $1.25 per share upon the conversion in full of the Convertible Note. The Series 5 Preferred Stock cannot be converted to the extent that, after giving effect to such conversion, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Common Stock. The Series 5 Preferred Stock is perpetual and therefore has no expiration date.